Filing Details

Accession Number:
0001093557-23-000096
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-04-05 16:56:59
Reporting Period:
2023-04-03
Accepted Time:
2023-04-05 16:56:59
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1093557 Dexcom Inc DXCM Surgical & Medical Instruments & Apparatus (3841) 330857544
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1286858 R Kevin Sayer 6340 Sequence Drive
San Diego CA 92121
President Ceo And Chairman Of Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-04-03 5,995 $113.83 342,274 No 4 S Direct
Common Stock Disposition 2023-04-03 11,218 $114.39 331,056 No 4 S Direct
Common Stock Disposition 2023-04-03 3,599 $115.70 327,457 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. On November 1, 2022, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended.
  2. This transaction was executed in multiple trades at prices ranging from $113.33 to $114.04. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
  3. Included in this number are 115,682 unvested restricted stock units, 54,422 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 43,336 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 17,924 of which were granted on March 8, 2021 and shall vest through March 8, 2024.
  4. This transaction was executed in multiple trades at prices ranging from $114.065 to $115.02. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
  5. This transaction was executed in multiple trades at prices ranging from $115.435 to $116.03. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.